Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term prophylaxis and on-demand study of recombinant von Willebrand factor in severe von Willebrand disease
NL-OMON52575Phase 3Active, not recruiting
- Sponsor
- Baxalta
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of vonicog alfa in von Willebrand disease (VWD) (6 cohorts), sponsored by Baxalta. Primary endpoint: Spontaneous annualized bleeding rate during prophylaxis. Started May 2019; status: active, not recruiting.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON52575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52575.